Dividend Investing Ideas Center
Critical Facts You Need to Know About Preferred Stocks
Have you ever wished for the safety of bonds, but the return potential...
Rating
Sector Rating
Recommendation *
Avoid
Neutral
Fair
Quality
Rating Breakdown
Avg.
Relative Strength
The relative strength of a dividend stock indicates whether the stock is uptrending or not. The major determining factor in this rating is whether the stock is trading close to its 52-week-high.
Overall Yield Attractiveness
If a stock’s yield is above or near the market average then it will be rated higher within this parameter. High dividend yields (usually over 10%) should be considered extremely risky, while low dividend yields (1% or less) are simply not very beneficial to long-term investors.
Dividend Reliability
A stock’s dividend reliability is determined by a healthy payout ratio that is higher than other stocks. A company that pays out close to half its earnings as dividends and retains the other half of earnings has ample room to grow its business and pay out more dividends in the future.
Dividend Uptrend
A stock’s Dividend Uptrend rating is dependent on the company’s price-to-earnings (P/E) ratio to evaluate whether or not a stock’s dividend is likely to trend upward. If a stock is valued near, or slightly below the market average, research has shown that the market expects the stock’s dividend to increase.
Earnings Growth
A stock’s Earnings Growth rating evaluates a company’s expected EPS for the current financial year and compares it to next financial year’s expected EPS. Stocks with single-digit growth estimates will have a higher rating than others, as our research has shown that well-established dividend-paying companies have modest earnings growth estimates.
You take care of your investments. We like that.
Upgrade to Premium to access your Watchlist and more.
First Trust NYSE Arca Biotechnology Index Fund
ETF
FBT
Payout Change
No Change
Price as of:
$150.16
+1.07
+0.72%
primary theme
Health Care Sector Equity
FBT (ETF)
First Trust NYSE Arca Biotechnology Index Fund
Payout Change
No Change
Price as of:
$150.16
+1.07
+0.72%
primary theme
Health Care Sector Equity
FBT (ETF)
First Trust NYSE Arca Biotechnology Index Fund
Payout Change
No Change
Price as of:
$150.16
+1.07
+0.72%
primary theme
Health Care Sector Equity
Name
Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
Vitals
YTD Return
-2.6%
1 yr return
1.9%
3 Yr Avg Return
6.6%
5 Yr Avg Return
2.5%
Net Assets
$1.29 B
Holdings in Top 10
38.8%
52 WEEK LOW AND HIGH
$149.1
$123.32
$165.37
Expenses
OPERATING FEES
Expense Ratio 0.55%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover N/A
Redemption Fee N/A
Min Investment
Standard (Taxable)
N/A
IRA
N/A
Fund Classification
Fund Type
Exchange Traded Fund
Name
Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
FBT - Profile
Distributions
- YTD Total Return -2.6%
- 3 Yr Annualized Total Return 6.6%
- 5 Yr Annualized Total Return 2.5%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.23%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Quarterly
Fund Details
-
Legal NameFirst Trust NYSE Arca Biotechnology Index Fund
-
Fund Family NameFirst Trust
-
Inception DateJun 19, 2006
-
Shares Outstanding9550002
-
Share ClassN/A
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerRoger Testin
Fund Description
The Fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the Index. The Fund, using an indexing investment approach, attempts to replicate, before fees and expenses, the performance of the Index. The Index is developed, maintained and sponsored by ICE Data Indices, LLC (the “Index Provider”). The Index Provider reserves the right to, at any time, change the number of stocks comprising the Index by adding or deleting one or more stocks, or replacing one or more stocks contained in the Index with one or more substitute stocks of its choice, if in the Index Provider's discretion such addition, deletion or substitution is necessary or appropriate to maintain the quality and/or character of the Index.The Index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody based technology, lipid/liposome technology and genomics. In order to be eligible for inclusion in the Index, a security must be listed on a qualifying U.S. securities exchange, be issued by a company with a market capitalization of at least $1 billion, have an average daily trading value of at least $1 million over the prior three months and have a current last-traded price of greater than $3. The securities selected for inclusion in the Index are equally weighted. Once included in the Index, it is required that a security maintain a market capitalization of at least $900 million, an average daily trading value of at least $900,000 over the prior three months and a current last-traded price of greater than $1.The Index is rebalanced and reconstituted quarterly and the Fund will make corresponding changes to its portfolio shortly after the Index changes are made public. The Index’s quarterly rebalance and reconstitution schedule may cause the Fund to experience a higher rate of portfolio turnover. The Fund will be concentrated in an industry or a group of industries to the extent that the Index is so concentrated. As of March 31, 2022, the Index was composed of 30 securities and the Fund had significant investments in health care companies, although this may change from time to time. To the extent the Fund invests a significant portion of its assets in a given jurisdiction or investment sector, the Fund may be exposed to the risks associated with that jurisdiction or investment sector.
Read More
FBT - Performance
Return Ranking - Trailing
| Period | FBT Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -2.6% | -25.6% | 23.4% | 22.35% |
| 1 Yr | 1.9% | -30.0% | 21.8% | 5.99% |
| 3 Yr | 6.6%* | -18.7% | 19.7% | 38.06% |
| 5 Yr | 2.5%* | -14.7% | 15.3% | 43.61% |
| 10 Yr | 11.0%* | -6.2% | 15.7% | 14.15% |
* Annualized
Return Ranking - Calendar
| Period | FBT Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2022 | -4.8% | -53.9% | 11.7% | 12.73% |
| 2021 | -1.8% | -22.3% | 18.5% | 68.10% |
| 2020 | 4.1% | -4.7% | 41.4% | 57.79% |
| 2019 | 4.6% | -10.2% | 13.1% | 60.14% |
| 2018 | -0.1% | -5.7% | 26.9% | 26.52% |
Total Return Ranking - Trailing
| Period | FBT Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -2.6% | -41.2% | 23.4% | 22.91% |
| 1 Yr | 1.9% | -30.0% | 28.3% | 10.73% |
| 3 Yr | 6.6%* | -18.7% | 19.7% | 39.26% |
| 5 Yr | 2.5%* | -14.7% | 15.3% | 47.52% |
| 10 Yr | 11.0%* | -6.2% | 15.7% | 20.56% |
* Annualized
Total Return Ranking - Calendar
| Period | FBT Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2022 | -4.8% | -53.9% | 11.7% | 12.73% |
| 2021 | -1.8% | -22.3% | 18.5% | 68.10% |
| 2020 | 4.1% | -4.7% | 41.4% | 57.79% |
| 2019 | 4.6% | -10.2% | 13.1% | 60.87% |
| 2018 | -0.1% | -5.7% | 26.9% | 31.06% |
FBT - Holdings
Concentration Analysis
| FBT | Category Low | Category High | FBT % Rank | |
|---|---|---|---|---|
| Net Assets | 1.29 B | 732 K | 46.2 B | 37.70% |
| Number of Holdings | 31 | 21 | 473 | 93.19% |
| Net Assets in Top 10 | 500 M | 2.18 K | 21.6 B | 40.31% |
| Weighting of Top 10 | 38.79% | 12.3% | 80.8% | 80.10% |
Top 10 Holdings
- United Therapeutics Corp 4.55%
- Grifols SA ADR 4.54%
- Intercept Pharmaceuticals Inc 4.30%
- Seattle Genetics Inc 4.03%
- Gilead Sciences Inc 3.97%
- Sarepta Therapeutics Inc 3.95%
- Regeneron Pharmaceuticals Inc 3.93%
- Alkermes PLC 3.87%
- Alnylam Pharmaceuticals Inc 3.84%
- IQVIA Holdings Inc 3.84%
Asset Allocation
| Weighting | Return Low | Return High | FBT % Rank | |
|---|---|---|---|---|
| Stocks | 99.87% | 85.37% | 106.13% | 27.23% |
| Cash | 0.13% | -0.10% | 9.01% | 72.77% |
| Preferred Stocks | 0.00% | 0.00% | 7.86% | 49.21% |
| Other | 0.00% | -22.99% | 3.38% | 54.45% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 49.74% |
| Bonds | 0.00% | 0.00% | 12.39% | 48.17% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | FBT % Rank | |
|---|---|---|---|---|
| Healthcare | 100.00% | 59.26% | 100.00% | 26.70% |
| Utilities | 0.00% | 0.00% | 0.00% | 46.07% |
| Technology | 0.00% | 0.00% | 22.69% | 50.79% |
| Real Estate | 0.00% | 0.00% | 7.13% | 49.74% |
| Industrials | 0.00% | 0.00% | 7.02% | 49.74% |
| Financial Services | 0.00% | 0.00% | 1.85% | 60.73% |
| Energy | 0.00% | 0.00% | 0.00% | 46.07% |
| Communication Services | 0.00% | 0.00% | 9.11% | 49.74% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 53.40% |
| Consumer Cyclical | 0.00% | 0.00% | 14.20% | 48.69% |
| Basic Materials | 0.00% | 0.00% | 14.83% | 63.87% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | FBT % Rank | |
|---|---|---|---|---|
| US | 91.80% | 53.67% | 104.41% | 20.42% |
| Non US | 8.07% | 0.00% | 45.40% | 68.59% |
FBT - Expenses
Operational Fees
| FBT Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.55% | 0.08% | 3.13% | 76.29% |
| Management Fee | 0.40% | 0.00% | 1.25% | 9.29% |
| 12b-1 Fee | 0.00% | 0.00% | 1.00% | 14.12% |
| Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
| FBT Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 0.00% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
| FBT Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| FBT Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | N/A | 0.00% | 238.00% | 22.00% |
FBT - Distributions
Dividend Yield Analysis
| FBT | Category Low | Category High | FBT % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 2.44% | 55.61% |
Dividend Distribution Analysis
| FBT | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Quarterly | Annually | Quarterly | Annually |
Net Income Ratio Analysis
| FBT | Category Low | Category High | FBT % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.23% | -2.54% | 1.92% | 50.89% |
Capital Gain Distribution Analysis
| FBT | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Sep 30, 2015 | $0.020 | OrdinaryDividend |
| Jun 30, 2015 | $0.065 | OrdinaryDividend |
| Mar 31, 2015 | $0.048 | OrdinaryDividend |
| Dec 31, 2014 | $0.052 | OrdinaryDividend |
| Jun 30, 2008 | $0.270 | OrdinaryDividend |
FBT - Fund Manager Analysis
Managers
Roger Testin
Start Date
Tenure
Tenure Rank
Jun 19, 2006
15.96
16.0%
Roger F. Testin, CFA, was born in 1966. Mr. Testin earned a B.S. in Accounting from the University of Illinois and has an MBA in Finance from the University of Chicago. He has been with First Trust Advisors L.P. since 2001 and he is a Portfolio Manager and Senior Vice President. As Product Manager for the VA’s, SMA’s and International Managed Products, Mr. Testin shall be responsible for the daily implementation and execution of the strategies for these product vehicles on behalf of the Investment Committee.
Daniel Lindquist
Start Date
Tenure
Tenure Rank
Jun 19, 2006
15.96
16.0%
Daniel J. Lindquist, CFA, was born in 1970. Mr. Lindquist earned a B.A. in Business Economics from Wheaton College and has an MBA in Finance from the University of Chicago. He has been with First Trust Advisors L.P. since 2004 and is a Managing Director. Mr. Lindquist is the Chairman of the Investment Committee and is responsible for the overall supervision of the Separate Managed Accounts.
Jon Erickson
Start Date
Tenure
Tenure Rank
Jun 19, 2006
15.96
16.0%
Jon C. Erickson, CFA, was born in 1966. Mr. Erickson earned a B.S. in Computer Science from the University of Illinois and has an MBA from the University of Illinois in Finance. He has been with First Trust Advisors L.P. since 1994 and he is a Portfolio Manager and Senior Vice President. As the head of FTA’s Equity Research Group, Mr. Erickson shall be responsible for determining the securities to be purchased and sold by Funds that do not utilize quantitative investment strategies on behalf of the Investment Committee.
David McGarel
Start Date
Tenure
Tenure Rank
Jun 19, 2006
15.96
16.0%
David G. McGarel, CFA, was born in 1966. Mr. McGarel earned a B.S. in Accounting from the University of Notre Dame. He has been with First Trust Advisors L.P. since 1997 and he is a Managing Director, Chief Operating Officer and the Chief Investment Officer. As head of FTA’s Strategy Research Group, Mr. McGarel shall be responsible for developing and implementing quantitative investment strategies for those Funds that have investment policies that require them to follow such strategies, on behalf of the Investment Committee.
Stan Ueland
Start Date
Tenure
Tenure Rank
Nov 08, 2006
15.57
15.6%
Mr. Ueland joined First Trust Advisors as a Vice President in August 2005 and has been a Senior Vice President of First Trust and FTP since September 2012. At First Trust, he plays an important role in executing the investment strategies of each portfolio of exchange-traded funds advised by First Trust. Before joining First Trust, he was vice president of sales at BondWave LLC from May 2004 through August 2005, an account executive for Mina Capital Management LLC and Samaritan Asset Management LLC from January 2003 through May 2004, and a sales consultant at Oracle Corporation from January 1997 through January 2003.
Chris Peterson
Start Date
Tenure
Tenure Rank
Mar 18, 2016
6.21
6.2%
Chris A. Peterson, CFA was born in 1975. Mr. Peterson earned a B.S in Finance from Bradley University and has an MBA from the University of Chicago Booth School of Business with concentrations in Analytic Finance & Accounting. He has been with First Trust Advisors L.P. since 2000. As head of FTA’s Portfolio Advisor’s Strategy Research Group, Mr. Peterson shall be responsible for developing and implementing quantitative equity strategies on behalf of the Investment Committee.
Erik Russo
Start Date
Tenure
Tenure Rank
Dec 31, 2020
1.41
1.4%
Mr. Russo is a Vice President of First Trust. He is responsible for implementing the investment strategies of each portfolio of exchange-traded funds advised by First Trust in his role as a Portfolio Manager. Mr. Russo joined First Trust in January of 2010.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.26 | 2.12 |
